SCHEMBL5118330

SCHEMBL5118330

CCOC1Oc2c(c(=O)oc3ccc(Br)cc23)C1c1c(O)c2cc(Br)ccc2oc1=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 3/20 0.46
CA9 Q16790 3/20 0.46
PIM1 P11309 2/20 0.37
NQO1 P15559 4/20 0.35
ESR1 P03372 1/20 0.34
ESR2 Q92731 1/20 0.34
CSNK2A2 P19784 3/20 0.33
CSNK2B P67870 3/20 0.33
CSNK2A1 P68400 3/20 0.33
ALDH1A1 P00352 1/20 0.33
USP2 O75604 1/20 0.33
KCNH2 Q12809 1/20 0.33
ALOX5 P09917 2/20 0.33
CDC7 O00311 1/20 0.33
PIM3 Q86V86 1/20 0.33
CSNK2A3 Q8NEV1 1/20 0.33
PIM2 Q9P1W9 1/20 0.33
LMNA P02545 1/20 0.32
TSHR P16473 1/20 0.32
PRNP P04156 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5119698 0.89 PRNP (0.40) NQO1ESR1ESR2ALDH1A1TSHR
SCHEMBL5111977 0.88 NQO1 (0.48) NQO1CSNK2A2CSNK2BCSNK2A1ALDH1A1
SCHEMBL5115168 0.87 NQO1 (0.47) NQO1ALDH1A1TSHRRXFP1
SCHEMBL5125494 0.87 NQO1 (0.47) NQO1ALDH1A1PRNPRXFP1
SCHEMBL5114980 0.86 NQO1 (0.52) CA12CA9NQO1ALDH1A1TSHR
SCHEMBL5120322 0.84 NQO1 (0.46) NQO1ALDH1A1TSHR
SCHEMBL5114210 0.82 ALDH1A1 (0.47) NQO1ALDH1A1LMNATSHRPRNP
SCHEMBL5340548 0.81 CA12 (0.49) CA12CA9PIM1NQO1CSNK2A2
SCHEMBL5115619 0.80 NQO1 (0.38) NQO1ALDH1A1USP2LMNARXFP1
SCHEMBL5125455 0.79 TP53 (0.38) NQO1ALDH1A1USP2TSHRRXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7384975-B2 Substituted furochromenes, preparation thereof and their antiinflammatory action GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) 2008-06-10 US disclosed
US-20060148889-A1 Substituted furochromenes, preparation thereof and their antiinflammatory action PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) 2006-07-06 US disclosed
EP-1648902-A1 SUBSTITUTED FUROCHROMENES, PREPARATION THEREOF AND THEIR ANTIINFLAMMATORY ACTION PLIVA-ISTRAZIVACKI INSTITUT d.o.o. (HR) 2006-04-26 EP disclosed
WO-2005010007-A1 SUBSTITUTED FUROCHROMENES, PREPARATION THEREOF AND THEIR ANTIINFLAMMATORY ACTION PLIVA- ISTRAZIVACKI INSTITUT D.O.O. (HR) 2005-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148889-A1 Substituted furochromenes, preparation thereof and their antiinflammatory action CYP11B2, CYP11B1, LTC4S CA12 3497/4885CA9 3170/4885PIM1 4116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.